article · JAMIA Open

Using machine learning algorithms to optimize treatment with high-cost biologics in a national cohort of patients with inflammatory bowel disease

Jason K. Hou
Francesca Cunningham
Codey Pham
Shubhada Sansgiry
Ji Zhu
Tiffany M. Tang
Jessica A Baker
Tony Van
Peter Richardson
Akbar K. Waljee

2025Open accessUniversity Of Global Health Equity

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

Prediction models, particularly RF+, may aid in optimizing biologic therapy for CD and UC by identifying patients at higher risk of flare following a biosimilar switch.

Research topics

Biosimilars and Bioanalytical Methods
Inflammatory Bowel Disease
Pharmacogenetics and Drug Metabolism

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1093/jamiaopen/ooaf162

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.